Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aim: To evaluate the efficacy and safety of a triple fixed-dose combination (FDC) therapy of dapagliflozin + glimepiride + metformin hydrochloride extended-release (DAPA + GLIM + MET ER) tablets in Indian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by combination of GLIM + MET.
Materials And Methods: A phase III, randomized, open-label, active-controlled study was conducted for a maximum 30 weeks (primary treatment [16 weeks]; uptitration [12 weeks] and follow-up [2 weeks]). Eligible patients were randomized in a 1:1 ratio to receive either the FDC of DAPA + GLIM + MET ER or the FDC of GLIM + MET prolonged-release (PR) once-daily. The primary efficacy endpoint was a change in glycated haemoglobin (HbA1c) from baseline to week 16.
Results: The mean reduction in HbA1c from baseline to week 16 was significantly greater with the FDC of DAPA + GLIM + MET ER compared to the FDC of GLIM + MET PR (-1.98% ± 1.01% vs. -1.64% ± 0.86%, p = 0.0047). The mean reduction in HbA1c from baseline to week 12 was significantly greater with the FDC of DAPA + GLIM + MET ER versus dual FDC (p < 0.0001). The proportion of patients achieving HbA1c <7.0% was significantly greater with the FDC of DAPA + GLIM + MET ER versus dual FDC at week 12 (19.1% vs. 6.5%; p = 0.0002) and week 16 (52.6% vs. 36.7%; p = 0.0015). A significant decrease in HbA1c, fasting and post-prandial blood glucose from baseline to weeks 12, 16, and 28 was observed in both arms. The incidence of TEAEs was similar across both arms.
Conclusion: This study demonstrated that the FDC of DAPA + GLIM + MET ER tablets once daily was significantly better than dual FDC in achieving glycaemic control in patients with poorly controlled T2DM. Both treatments were well-tolerated.
Trial Registration: CTRI/2022/03/041424, registered on 28 March 2022.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885079 | PMC |
| http://dx.doi.org/10.1111/dom.16218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Primary lymphomas in urinary bladder: a clinicopathological analysis of 23 cases].
Zhonghua Bing Li Xue Za Zhi
September 2025
Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
To investigate the clinicopathological features, diagnosis and differential diagnosis of primary bladder lymphoma. A retrospective study was conducted on 23 cases of primary bladder lymphoma diagnosed at Beijing Friendship Hospital of Capital Medical University between February 2010 and April 2024. The clinicopathological data were collected and analyzed, and literature was reviewed.
View Article and Find Full Text PDFA Cost-Effective Treatment Approach Using Rosuvastatin+Clopidogrel Fixed Dose Combination (FDC) to Enhance Adherence: A Retrospective, Non-comparative, Real-World Indian Study.
Cureus
August 2025
Scientific Services, USV Private Limited, Mumbai, IND.
Background Medication adherence is mostly influenced by cost, and disease management can be achieved through cost-effective combinations. The present study aimed to evaluate adherence to the cost-effective fixed dose combination (FDC) of rosuvastatin and clopidogrel in the management of cardiovascular diseases (CVD). Methods This retrospective, non-randomized, non-comparative, multicenter study was conducted across 100 healthcare centers in India.
View Article and Find Full Text PDFBRIDGE-DS study: evaluating the effectiveness and safety of dapagliflozin/sitagliptin combination in type 2 diabetes mellitus patients with heart failure.
Cardiovasc Endocrinol Metab
December 2025
Department of Endocrinology, Scientific Services, USV Pvt. Ltd, Mumbai, Maharashtra, India.
Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.
Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.
Transcriptomic activation of immune cell trafficking predicts antidepressant response to minocycline.
J Affect Disord
September 2025
King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, SE5 9RT, UK; National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College Lond
Although inflammation has been suggested as a promising therapeutic target for major depressive disorder (MDD), uncertainty remains about how to recognise individuals who may benefit from anti-inflammatory treatments. Transcriptomic profiles provide an important tool to identify relevant biological mechanisms associated with response. In this study, we investigate: i) the ability of transcriptomic profiles to predict antidepressant response to anti-inflammatory treatment with minocycline, and ii) the effect of minocycline on transcriptomic profiles based on the antidepressant response.
View Article and Find Full Text PDFBehavioral investigation of reactive and neoplastic lymphocytes in human lymph nodes in 4D.
PLoS One
September 2025
Institute for general pharmacology and toxicology, Goethe University, University Hospital, Frankfurt/Main, Hesse, Germany.
This study deals with a 4D investigation of lymphocytes in human tissue under reactive and neoplastic conditions. The immune system's response to pathogens highly depends on cell interaction and movement, which makes it essential to analyze these dynamics. To achieve this, we observed cells and their movement in 4D.
View Article and Find Full Text PDF